FrancophonIA/ELRC3.0 huggingface dataset:
English: Primula flower preparations may also be found in combination with other herbal substances in some herbal medicines.
Estonian: Mõnes taimses ravimis võib esineda nurmenukuõie valmistisi ka kombinatsioonis teiste taimsete ainetega.
English: This summary is not intended to provide practical advice on how to use medicines containing primula flower.
Estonian: Hindamisaruandes ei anta nurmenukuõit sisaldavate ravimite kasutamise praktilisi nõuandeid.
English: Herbal medicines containing these primula flower preparations are usually available as herbal tea to be drunk and in liquid forms to be taken by mouth.
Estonian: Neid nurmenukuõie valmistisi sisaldavaid taimseid ravimeid turustatakse tavaliselt joodava taimeteena või suukaudse vedela ravimvormina.
English: The HMPC concluded that, on the basis of its long-standing use, these primula flower primula flower preparations can be used as an expectorant (a medicine that helps bring up phlegm) for coughs associated with colds.
Estonian: Taimsete ravimite komitee järeldas, et lähtudes pikaajalisest kasutamisest tohib neid nurmenukuõie valmistisi kasutada ekspektorandina (röga lahtistava ainena) külmetushaigustega kaasneva köha korral.
English: How are primula flower medicines approved in the EU?
Estonian: Kuidas antakse Euroopa Liidus nurmenukuõit sisaldavate ravimite müügiluba?
English: The HMPC conclusions on the use of these primula flower medicines for coughs are based on their ‘traditional use' .
Estonian: Taimsete ravimite komitee järeldused nende nurmenukuõie valmistisi sisaldavate ravimite kasutamise kohta köha korral põhinevad nende traditsioonilisel kasutusel.
English: What are the risks associated with primula flower medicines?
Estonian: Mis riskid nurmenukuõit sisaldavate ravimitega kaasnevad?
English: For more information about treatment with primula flower medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Estonian: Kui vajate nurmenukuõit sisaldavate ravimitega toimuva ravi kohta lisateavet, lugege palun ravimi pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: What are the HMPC conclusions on its medicinal uses?
Estonian: Mis on taimsete ravimite komitee järeldused nurmenukuõie meditsiiniliste kasutusalade kohta?
English: In its assessment, the HMPC considered laboratory studies which showed primula flower increased production of airway secretions, making phlegm less thick and easier to expel.
Estonian: Taimsete ravimite komitee uuris hinnangu andmisel laborikatseid, mis tõendasid, et nurmenukuõis soodustab hingamisteedes eritise tekkimist, mis vedeldab röga ja seda saab kergemini välja köhida.
English: Primula flower
Estonian: Nurmenukuõis
English: For practical information about using primula flower medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
Estonian: Kui vajate nurmenukuõit sisaldavate ravimite kasutamise kohta praktilisi nõuandeid, lugege ravimi pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Primula flower is the common name for the flowers of the plant Primula veris L. and/or Primula elatior (L.) Hill.
Estonian: Nurmenukuõis on hariliku nurmenuku (Primula veris L.) ja/või kõrge priimula (Primula elatior (L.) Hill õite üldnimetus.
English: EMA/237735/2019 EMEA/H/C/004951
Estonian: aprill 2019 EMA/237735/2019 EMEA/H/C/004951
English: To support this claim, the company referred to published data and provided an expert opinion.
Estonian: Selle väite toetuseks viitas ettevõte avaldatud andmetele ja esitas eksperdiarvamuse.
English: Data from clinical studies also showed differences in the safety profile of the two active substances.
Estonian: Kliiniliste uuringute andmed näitasid samuti erinevusi kahe toimeaine ohutusprofiilides.
English: The company that applied for authorisation is Teva B.V.
Estonian: Müügiluba taotles ettevõte Teva B.V.
English: On 26 April 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Cabazitaxel Teva, intended for the treatment of prostate cancer.
Estonian: 26. aprillil 2019 võttis inimravimite komitee vastu negatiivse arvamuse, soovitades keelduda andmast müügiluba ravimile Cabazitaxel Teva, mida kavatseti kasutada eesnäärmevähi raviks.
English: What is Cabazitaxel Teva?
Estonian: Mis on Cabazitaxel Teva?
English: This means that Cabazitaxel Teva was intended to be similar to a ‘reference medicine' containing the same active substance and already authorised in the European Union.
Estonian: See tähendab, et Cabazitaxel Teva pidi olema sarnane sama toimeainet sisaldava võrdlusravimiga, millel juba on Euroopa Liidus müügiluba.
English: The company claimed that cabazitaxel is a derivative of docetaxel, and that the active substances do not differ significantly in their safety and effectiveness.
Estonian: Ettevõte väitis, et kabasitakseel on dotsetakseeli derivaat ja et nende toimeainete ohutus ja efektiivsus ei erine olulisel määral.
English: Furthermore, patients receiving cabazitaxel are exposed to the unchanged substance plus two active breakdown products, which are not formed when docetaxel is given.
Estonian: Peale selle puutuvad kabasitakseeli saavad patsiendid kokku muutumatu aine ja kahe aktiivse lagunemissaadusega, mida ei teki dotsetakseeli manustamisel.
English: The company informed the CHMP that there are no ongoing clinical trials with Cabazitaxel Teva in the EU.
Estonian: Ettevõte teatas inimravimite komiteele, et Euroopas Cabazitaxel Teva kliinilisi uuringuid praegu ei toimu.
English: The company made reference to two medicines, Jevtana (containing cabazitaxel) and Taxotere (containing docetaxel, see below for more details).
Estonian: Ettevõte kasutas võrdlusravimina kahte ravimit - Jevtanat (sisaldab kabasitakseeli) ja Taxoteret (sisaldab dotsetakseeli; täpsemalt vt allpool).
English: Based on these findings, the CHMP was of the opinion that it cannot be concluded that cabazitaxel and docetaxel do not differ significantly with regard to safety and effectiveness.
Estonian: Nende tulemuste põhjal oli inimravimite komitee arvamusel, et ei ole võimalik järeldada, et kabasitakseeli ja dotsetakseeli ohutus ja efektiivsus ei erine olulisel määral.
English: Cabazitaxel Teva was to be used in combination with prednisone or prednisolone (anti-inflammatory medicines) in patients who have previously been treated with docetaxel (another cancer medicine).
Estonian: Cabazitaxel Tevat kavatseti kasutada koos prednisooni või prednisolooniga (põletikuvastased ravimid) patsientidel, keda on varem ravitud dotsetakseeliga (samuti vähiravim).
English: The applicant also made reference to another medicine, Taxotere, which contains docetaxel.
Estonian: Taotleja võrdles ravimit ka teise ravimiga - dotsetakseeli sisaldava Taxoterega.
English: Cabazitaxel Teva was to be used when the cancer had spread to other parts of the body (metastatic) despite treatments to prevent the production of testosterone or after surgical removal of the testes (castration).
Estonian: Cabazitaxel Tevat kavatseti kasutada siis, kui vähk on levinud organismis ka mujale (metastaatiline), vaatamata testosterooni teket ennetavale ravile või pärast munandite kirurgilist eemaldamist (kastreerimine).
English: Because Cabazitaxel Teva was developed as a hybrid medicine, the company presented data from the published literature to demonstrate that it is similar to Jevtana.
Estonian: Cabazitaxel Teva töötati välja hübriidravimina, mistõttu ettevõte esitas avaldatud kirjandusest pärit andmed Jevtanaga sarnasuse tõendamiseks.
English: Cabazitaxel also affects non-cancer cells, such as blood and nerve cells, which can cause side effects.
Estonian: Kabasitakseel mõjub ka muudele rakkudele peale vähirakkude, näiteks vere- ja närvirakkudele, mis võib põhjustada kõrvalnähte.
English: Additionally, laboratory data suggest that cabazitaxel can be effective at treating cancer that is resistant to docetaxel.
Estonian: Peale selle näitavad laboriandmed, et kabasitakseel võib olla efektiivne dotsetakseelile resistentse vähi ravis.
English: The CHMP did not agree that the data presented by the company were sufficient to support the claim that cabazitaxel and docetaxel should be considered the same active substance.
Estonian: Inimravimite komitee ei nõustunud, et ettevõtte esitatud andmed on piisavad tõendamaks, et kabasitakseeli ja dotsetakseeli tuleks käsitleda samade toimeainetena.
English: Although cabazitaxel is a derivative of docetaxel, laboratory studies have shown that cabazitaxel and docetaxel have different properties, for example cabazitaxel can cross the blood-brain barrier while docetaxel cannot.
Estonian: Kuigi kabasitakseel on dotsetakseeli derivaat, on laboriuuringud näidanud, et kabasitakseelil ja dotsetakseelil on erinevad omadused, näiteks suudab kabasitakseel läbida hematoentsefaalbarjääri, dotsetakseel aga mitte.
English: Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom26.
English: Thus Taxotere cannot be used to support the application for Cabazitaxel Teva and the CHMP recommended that Cabazitaxel Teva be refused marketing authorisation.
Estonian: Seega ei ole võimalik kasutada Taxoteret Cabazitaxel Teva taotluse toetuseks ja inimravimite komitee soovitas keelduda müügiloa andmisest Cabazitaxel Tevale.
English: Cabazitaxel Teva is a cancer medicine that contains the active substance cabazitaxel.
Estonian: Cabazitaxel Teva on vähiravim, mis sisaldab toimeainena kabasitakseeli.
English: Cabazitaxel Teva was developed as a ‘hybrid medicine'.
Estonian: Cabazitaxel Teva töötati välja hübriidravimina.
English: How does Cabazitaxel Teva work?
Estonian: Kuidas Cabazitaxel Teva toimib?
English: There was no need for ‘bioequivalence' studies to investigate whether Cabazitaxel Teva is absorbed similarly to Jevtana to produce the same level of the active substance in the blood.
Estonian: Ravimi bioekvivalentsust (st kas Cabazitaxel Teva imendub organismis samamoodi nagu Jevtana, et tekitada veres sama toimeainesisalduse) ei olnud vaja uurida.
English: Cabazitaxel Teva is expected to work in the same way as the reference medicine, Jevtana.
Estonian: Cabazitaxel Teva eeldatav toime on samasugune võrdlusravimi Jevtana toimega.
English: This is because Cabazitaxel Teva is given by infusion into a vein, so the active substance is delivered straight into the bloodstream.
Estonian: Seda ei olnud vaja, sest ravimit Cabazitaxel Teva manustatakse veeniinfusioonina, mille abil satub toimeaine otse vereringesse.
English: It was to be available as a concentrate to be made into a solution for infusion (drip) into a vein.
Estonian: Seda kavatseti turustada infusioonilahuse kontsentraadina.
English: Refusal of the marketing authorisation for Cabazitaxel Teva (cabazitaxel)
Estonian: Cabazitaxel Teva (kabasitakseel) müügiloa andmisest keeldumine
English: What was Cabazitaxel Teva expected to be used for?
Estonian: Milleks kavatseti Cabazitaxel Tevat kasutada?
English: If another course of treatment is required, the interval between the two courses of treatment should be at least 3 months.
Estonian: Kui vaja on teist ravikuuri, peab kahe ravikuuri vahele jääma vähemalt 3 kuud.
English: Exzolt fluralaner
Estonian: Exzolt fluralaneer
English: Egg production may also be affected.
Estonian: See võib kahjustada ka munemist.
English: While handling the product people must not eat, drink or smoke.
Estonian: Ravimi käsitsemise ajal ei tohi süüa, juua ega suitsetada.
English: The full EPAR for Exzolt can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Exzolti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: The duration of effectiveness was between 6 weeks and 8 months, depending on the length of the production cycle and how effectively the farms prevented re-introduction of new mites into their houses.
Estonian: Efektiivsus püsis 6 nädalat kuni 8 kuud, olenevalt tootmistsüklist ja sellest, kui tõhusalt suudeti põllumajandusettevõtetes ennetada uute lestade sattumist kanalatesse.
English: The European Commission granted a marketing authorisation valid throughout the EU for Exzolt on 18 August 2017.
Estonian: Euroopa Komisjon andis Exzolti müügiloa, mis kehtib kogu Euroopa Liidus, 18/08/2017.
English: What is Exzolt and what is it used for?
Estonian: Mis on Exzolt ja milleks seda kasutatakse?
English: Exzolt is added to drinking water on two occasions, seven days apart.
Estonian: Exzolti lisatakse joogivette kahel korral seitsmepäevase vahega.
English: Exzolt reduced the number of mites by more than 99% in pullets and breeders and more than 98% in layers.
Estonian: Exzolt vähendas lestade arvu noorkanadel ja aretuskanadel enam kui 99% võrra ja munakanadel enam kui 98% võrra.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Exzolt's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Veterinaarravimite komitee järeldas, et Exzolti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Why is Exzolt approved?
Estonian: Miks Exzolt heaks kiideti?
English: It is not intended to provide practical advice on how to use Exzolt.
Estonian: Hindamisaruandes ei anta Exzolti kasutamise praktilisi nõuandeid.
English: The withdrawal period for meat from chickens treated with Exzolt is 14 days.
Estonian: Exzoltiga ravitud kanade liha keeluaeg on 14 päeva.
English: Other information about Exzolt?
Estonian: Muu teave Exzolti kohta
English: Since the veterinary medicine may be slightly irritating to skin and/or eyes, contact with skin, eyes and mucous membranes (moist body surfaces, such as the lining of the mouth) should be avoided.
Estonian: Kuna veterinaarravim võib põhjustada kerget naha- ja/või silmaärritust, tuleb vältida kokkupuudet naha, silmade ja limaskestadega (nt suu limaskest).
English: Exzolt contains the active substance fluralaner.
Estonian: Exzolt sisaldab toimeainena fluralaneeri.
English: The withdrawal period for eggs from chickens treated with Exzolt is ‘zero' days, which means there is no mandatory waiting time.
Estonian: Exzoltiga ravitud kanade munade keeluaeg on 0 päeva, mis tähendab, et keeluaega ei ole.
English: What are the risks associated with Exzolt?
Estonian: Millised riskid Exzoltiga kaasnevad?
English: This is a summary of the European public assessment report (EPAR) for Exzolt.
Estonian: See on ravimi Exzolt Euroopa avaliku hindamisaruande kokkuvõte.
English: It works by interfering with the way that signals are passed between nerve cells (neurotransmission) in the nervous system of parasites, resulting in paralysis and death of the mites.
Estonian: See mõjutab närvirakkudevahelist signaalivahetust (neurotransmissiooni) parasiitide närvisüsteemis, põhjustades lestade paralüüsi ja surma.
English: Fluralaner kills mites by acting on their nervous system after they have ingested the chicken's blood.
Estonian: Fluralaneer hävitab lestad, mõjutades nende närvisüsteemi pärast seda, kui lestad on imenud kana verd.
English: Exzolt is a veterinary medicine used to treat poultry red mite (Dermanyssus gallinae) infestation in pullets (young female chickens), breeders and layer hens.
Estonian: Exzolt on veterinaarravim, mida kasutatakse kanalesta (Dermanyssus gallinae) infestatsiooni raviks noorkanadel, aretuskanadel ja munakanadel.
English: Sufficient Exzolt is added to ensure the required dose is present in the volume of water that the chickens will consume in one day.
Estonian: Exzolti lisatakse piisavas koguses, et kanad saaksid ühe päeva joogiveest vajaliku annuse.
English: One of the houses on each of the farms was treated with Exzolt, the other house was left untreated.
Estonian: Igas põllumajandusettevõttes raviti ühe kanala linde Exzoltiga ning teise kanala linnud jäeti ravita.
English: Red mite infestations can cause irritation and restlessness of the bird, feather pecking and anaemia (low red blood cell counts).
Estonian: Kanalestainfestatsioon võib lindudel põhjustada ärritust ja rahutust, sulgede nokkimist ja aneemiat (vere punaliblede vähesus).
English: How is Exzolt used?
Estonian: Kuidas Exzolti kasutatakse?
English: For practical information about using Exzolt, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Estonian: Kui loomaomanikud või -pidajad vajavad Exzolti kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
English: Safety information has been included in the summary of product characteristics and the package leaflet for Exzolt, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Estonian: Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati Exzolti ohutusteave, kus on ka tervishoiuspetsialistide ja loomaomanike või -pidajate võetavad meetmed.
English: There are no known side effects.
Estonian: Exzoltil ei ole teadaolevaid kõrvaltoimeid.
English: Exzolt has been studied in a field study involving 9 farms with poultry red mite infestation, each with two similar houses with 550 to 100,000 chickens per house.
Estonian: Igas põllumajandusettevõttes oli kaks sarnast kanalat 550-100 000 linnuga kanala kohta.
English: What benefits of Exzolt have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Exzolti kasulikkus?
English: Exzolt is available as a solution for use in drinking water and can only be obtained with a prescription.
Estonian: Exzolt on retseptiravim ja seda turustatakse joogiveele lisatava lahusena.
English: Hands and contacted skin should be washed after use of the medicine.
Estonian: Pärast ravimi käsitsemist tuleb käsi ja ravimiga kokku puutunud nahapiirkonda pesta.
English: Poultry red mite is a parasite that feeds on the blood of hens.
Estonian: Kanalest on kanade verest toituv parasiit.
English: This means it kills parasites such as mites that feed on the skin of animals.
Estonian: Exzolti toimeaine fluralaneer toimib ektoparasititsiidina, mis tähendab, et see hävitab loomade nahast toituvad parasiidid, näiteks lestad.
English: How does Exzolt work?
Estonian: Kuidas Exzolt toimib?
English: Page 2/2©EMEA 2008
Estonian: lk 2/2©EMEA 2008
English: This usually disappears within one to four weeks.
Estonian: See kaob tavaliselt ühe kuni nelja nädalaga.
English: The marketing authorisation was renewed on 18 April 2005.
Estonian: Müügiluba pikendati 18. aprillil 2005.
English: The cats should be revaccinated every year.
Estonian: Kasse tuleb igal aastal uuesti vaktsineerida.
English: This summary was last updated on 24 October 2007.
Estonian: Kokkuvõtte viimane uuendus: 24-10-2007.
English: Immunisation against FeLV sub-group A provides full protection against all three sub-groups of the virus: A, B and C.
Estonian: Immuniseerimine FeLV A-alarühma vastu kaitseb täielikult viiruse kõigi kolme alarühma, A, B ja C vastu.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Purevax FeLV to MERIAL on 13 April 2000.
Estonian: Euroopa Komisjon väljastas Purevax FeLV müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele MERIAL 13. aprillil 2000.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) PUREVAX FELV EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE PUREVAX FELV Kokkuvõte üldsusele
English: The antibodies will help to protect against the disease caused by the virus.
Estonian: Antikehad aitavad kaitsta haiguse eest, mida see viirus esile kutsub.
English: Vaccines work by priming the immune system (the body's natural defences) how to defend itself against diseases.
Estonian: Vaktsiinid "õpetavad" immuunsüsteemi (keha loomulikke kaitsemehhanisme) ennast haiguse eest kaitsma.
English: In case of accidental self-injection seek medical advice immediately and show the Package Leaflet or the label to the doctor.
Estonian: Juhusliku iseenesele süstimise korral tuleb kohe pöörduda arsti poole ja näidata talle ravimi pakendi infolehte või etiketti.
English: Immunity starts at the latest two weeks after the second injection and lasts for a year.
Estonian: Immuunsus tekib hiljemalt kahe nädala möödumisel teisest süstist ja püsib ühe aasta.
English: The vaccine is used to prevent the symptoms of the disease and to prevent FeLV from remaining in the blood.
Estonian: Vaktsiini kasutatakse haigussümptomite ennetamiseks ja FeLV eemaldamiseks verest.
English: The first injection should be given in cats aged at least eight weeks, with a second injection three to five weeks later.
Estonian: Kasse süstitakse esmakordselt vähemalt kaheksa nädala vanuses ja teine süst tehakse kolm kuni viis nädalat hiljem.
English: Purevax FeLV should not be used in pregnant cats.
Estonian: Purevax FeLV-d ei tohi kasutada tiinetel kassidel.
English: When a cat is given the vaccine, the immune system recognises the FeLV proteins as ‘foreign' and makes antibodies against them.
Estonian: Kui kassile antakse vaktsiini, peab immuunsüsteem FeLV valke "võõrasteks" ja produtseerib nende vastu antikehi.
English: A 1 ml dose of Purevax FeLV is injected under the skin.
Estonian: 1 ml Purevax FeLV annus süstitakse naha alla.
English: The canarypox viruses do not spread or multiply in the cat but they do produce proteins from the FeLV genes.
Estonian: Canarypox virus ei levi ega paljune kassi kehas, kuid produtseerib FeLV geenidest valke.
English: The effectiveness of Purevax FeLV has been studied in several trials in laboratory conditions where cats were vaccinated and infected with FeLV.
Estonian: Purevax FeLV efektiivsust uuriti mitmes laboratoorses uuringus, kus kasse vaktsineeriti ja nakatati FeLVga.
English: The first evidence of FeLV infection occurred after six weeks in only a few of the kittens vaccinated with Purevax FeLV.
Estonian: Esimesed märgid FeLVga nakatumisest tekkisid kuue nädala pärast ainult mõnel Purevax FeLVga vaktsineeritud kassipojal.
English: Infection was seen from four weeks in non-vaccinated animals.
Estonian: Vaktsineerimata loomadel täheldati nakkust alates nelja nädala möödumisest.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Purevax FeLV exceed the risks for active immunisation of cats eight weeks of age or older against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease, and recommended that Purevax FeLV be given a marketing authorisation.
Estonian: Veterinaarravimite komitee otsustas, et Purevax FeLV kasulikkus kaheksanädalaste või vanemate kasside aktiivsel immuniseerimisel kasside leukeemia vastu püsiva vireemia ja sellega seotud haiguse ennetamiseks on suurem kui sellega kaasnevad ohud, ning soovitas anda Purevax FeLV-le müügiloa.
English: In the field, efficacy has been studied in one main study of kittens aged eight weeks or older, in which the effects of Purevax FeLV were compared with those of another vaccine against FeLV.
Estonian: Välitingimustes uuriti ravimi efektiivsust ühes põhiuuringus kaheksanädalaste ja vanemate kassipoegadega, milles Purevax FeLV toimeid võrreldi teise FeLV-vastase vaktsiini toimetega.
English: Purevax FeLV is a vaccine containing feline leukaemia virus (FeLV) recombinant canarypox virus (vCP97).
Estonian: Purevax FeLV on kasside leukeemiaviiruse (FeLV) rekombinantset Canarypox virus't (vCP97) sisaldav vaktsiin.
English: The vaccinated kittens were housed for up to 28 weeks with a group of kittens who were infected with FeLV.
Estonian: Vaktsineeritud kassipojad pandi koos FeLVga nakatatud kassipoegade rühmaga elama kuni 28 nädalaks.
English: In all trials, the main measure of effectiveness was the presence of antibodies against the virus and infectious FeLV in the vaccinated kittens' blood.
Estonian: Efektiivsust mõõdeti selles uuringus põhiliselt viiruse antikehade ja nakkava FeLV olemasolu järgi vaktsineeritud kassipoegade veres.